Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis

INTRODUCTION: The PrismRA(®) test identifies rheumatoid arthritis (RA) patients who are unlikely to respond to anti-tumor necrosis factor (anti-TNF) therapies. This study evaluated the clinical and financial outcomes of incorporating PrismRA into routine clinical care of RA patients. METHODS: A deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Martin J., Kivitz, Alan J., Pappas, Dimitrios A., Kremer, Joel M., Zhang, Lixia, Jeter, Anna, Withers, Johanna B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695768/
https://www.ncbi.nlm.nih.gov/pubmed/32797404
http://dx.doi.org/10.1007/s40744-020-00226-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695768/
https://www.ncbi.nlm.nih.gov/pubmed/32797404
http://dx.doi.org/10.1007/s40744-020-00226-3

Ejemplares similares